Compliance · State rules

Office-use compounding in Mississippi

Non-patient-specific supply prohibited; patient-specific office administration expressly permitted

USPeptideRx EditorialLast reviewed: August 30, 2026

Mississippi answers both halves of this question in a single paragraph, and quoting either half alone gets the state wrong. Pharmacies may not offer compounded human drug products to practitioners or to other pharmacies for resale or dispensing — and pharmacies MAY compound patient-specific medications for office administration by a practitioner. So the bar is on the product being non-patient-specific, not on the setting or the sterility. Mississippi is also the only state in this file that defines "office use" at all, and it does so in a place that misleads: inside a wholesale-licensure exemption, in a state whose compounding rule forbids the underlying transaction.

The governing rule

Mississippi’s office-use position is set by Miss. Admin. Code Pt. 3001, Art. XXXI ¶1.E. The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

Art. XXXI ¶1.E — both halves, as the rule writes them

Pharmacies shall not offer compounded human drug products to practitioners or to other pharmacies for resale or dispensing … Pharmacies may compound patient specific medications for office administration by a practitioner.

Art. XXXII ¶1.A(6) — the only definition of office use in this file, and it is not the office-use rule

The sale/purchase of a prescription drug or device by a 503a pharmacy to a licensed practitioner for office use, if the total annual dollar volume … does not exceed five percent (5%) of that pharmacy’s total annual prescription sales. In office use is defined as occurring in locations that are not serviced by a pharmacy permit

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The bar is on patient-specificity, not on the settingHigh confidence: Office administration by a practitioner is expressly contemplated and permitted, so long as the medication was compounded for a specific patient. What Mississippi forbids is supplying practitioners with non-patient-specific compounded product. A sentence saying Mississippi bans office use is therefore wrong in a way the rule refutes in its very next clause, which permits patient-specific compounding for office administration.
No sterility splitHigh confidence: The prohibition turns on whether the preparation is for an identified patient, not on whether it is sterile. There is no separate sterile rule to reach for.
The definition of office use, and why it is not the office-use ruleHigh confidence: Mississippi is one of the few states reviewed here that defines the term at all — Iowa is the other, and it defines it very differently. In Mississippi it appears inside a wholesale-distribution exemption — excluding from wholesale licensure a sale by a 503A pharmacy to a licensed practitioner for office use, capped at five per cent of the pharmacy’s total annual prescription sales — and it defines office use as occurring in locations not serviced by a pharmacy permit. The missing preposition at the start of that sentence is the rule’s own typography, reproduced here as written.That definition must never be published as Mississippi’s office-use rule. It exempts a transaction from a licensing scheme; it does not authorise compounding, and the compounding article forbids the underlying transaction it appears to describe. It is the most confusing artifact in this batch and a supplier will quote it.
The dispensing bar that catches compounded product specificallyHigh confidence: A physician who dispenses needs a dispensing permit, and the rule then bars that dispenser from dispensing compounded product that was compounded by a 503A pharmacy or an outsourcing facility. So the dispensing route does not open a side door for compounded stock — it closes one.
A host quirk worth knowing if you check this yourselfHigh confidence: Mississippi’s Secretary of State host inverts the usual fingerprint: it returned an access error and an empty body to a browser user agent, and the full one-megabyte rule document to a plain command-line client. Both were run as a controlled pair. If your first attempt fails, try the other kind of client before concluding the document is unavailable.
Last change, and one pending itemMedium confidence: The physician-dispensing article that carries the compounded-product bar took effect on 14 November 2024. A separate filing proposed on 22 April 2025 has no final filing and no effective date sixteen months later, and a board draft was adopted on 9 July 2026. Both retain the current text of the operative paragraph unchanged, but Mississippi’s compounding article is demonstrably in motion.

Mississippi at a glance

Mississippi office-use compounding summary, reviewed 2026-08-30
Human office use	Non-patient-specific prohibited; patient-specific office administration permitted
Sterile preparations	No split — the bar turns on patient-specificity
Quantity cap	None on the prohibited limb; the wholesale exemption caps at 5% of annual sales
Mandatory label legend	None
Board reporting	None for office use
Last change	Dispensing article effective November 2024; a filing pending since April 2025
Governing rule	Miss. Admin. Code Pt. 3001, Art. XXXI ¶1.E

Receiving 503B office stock in Mississippi

Mississippi has an outsourcing-facility credential under four different names, none of which is "outsourcing facility" — so a keyword search of its rules returns nothing and the obvious conclusion is wrong. It is also the strongest receiving-practice case in this file, and it splits three ways.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Mississippi asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence: A Sterile Product Outsourcing permit from the Board of Pharmacy, $300 biennially plus a $50 controlled-substance registration, per location, and it may not be held at the same location as a pharmacy permit. The literal phrase "outsourcing facility" returns no hits anywhere in the rules.The same credential is called four things across the state’s own documents: "Sterile Product Outsourcing" in the article, "Outsourcer" on the fee schedule, "Sterile Product Outsourcer" on the application list, and "503b Outsourcer" elsewhere in the rules. Searching for any one of them can produce a false negative, and concluding Mississippi has no category is the error that follows.
Does your practice need a permit?High confidence: This is the three-way case. A solo prescriber who only administers needs nothing. Where multiple providers administer controlled substances under one clinic federal registration, the clinic needs an ambulatory surgical or medical practice clinic permit, per location, at $300 initial and $100 renewal. And any physician who dispenses needs a physician dispensing permit at $350.The middle case is the one that surprises people, and it is entity-capable: the permit attaches to the clinic rather than to a practitioner, precisely because the providers are operating under a single clinic registration.
Administer vs dispenseHigh confidence: Administering is the clean case and needs no credential for a solo prescriber. Dispensing pulls in a permit — and then bars the permit holder from dispensing compounded product that a 503A pharmacy compounded. The same bar reaches product from an outsourcing facility, which is the opposite of the direction most states run.
Scheduled (controlled) stockHigh confidence: The Board issues a facility controlled-substance registration at $50. Controlled substances are also what trigger the clinic permit in the middle case above, where multiple providers administer them under one clinic federal registration.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Federal law is a second, independent constraint — a state prohibition is not the only thing standing in the way. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Mississippi compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

A filing proposed on 22 April 2025 still has no final filing and no effective date sixteen months later, and a board draft was adopted on 9 July 2026. Both keep the operative paragraph unchanged, so nothing on this page turns on them — but whether Mississippi is about to tighten, loosen or renumber its compounding article is outside what we can tell you.
We searched no case law, attorney-general opinions, board newsletters or disciplinary orders for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.